MDWD — MediWound Ltd.

MediWound Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $5.4 million, up 23% year-over-year from $4.4 million.
• Gross Profit: $0.9 million (16.5% of revenue), compared to $0.7 million (15.5%) in Q3 2024.
• R&D Expenses: Increased to $3.5 million from $2.5 million due to investments in the EscharEx VALUE Phase III study.
• SG&A Expenses: Rose to $4 million from $3.2 million, primarily due to marketing authorization holder costs.
• Operating Loss: $6.5 million, up from $5.1 million in Q3 2024.
• Net Loss: $2.7 million ($0.24 per share), improved from a net loss of $10.3 million ($0.98 per share) in the prior year.
• Adjusted EBITDA Loss: $5.4 million, compared to $3.7 million in Q3 2024.
• Cash Position: $60 million as of September 30, 2025, up from $44 million at year-end 2024.

2. Strategic Updates and Business Highlights

• EscharEx (Chronic Wounds): Enrollment in the VALUE Phase III trial for venous leg ulcers (VLU) is progressing, with 216 patients targeted across 40 sites. Positive FDA feedback received for the diabetic foot ulcer (DFU) program, with plans to initiate the study in H2 2026.
• Market Opportunity: Updated analysis suggests potential peak sales of $831 million for EscharEx, driven by favorable pricing assumptions due to recent Medicare reimbursement changes.
• NexoBrid (Severe Burns): Expanded manufacturing facility completed, increasing production capacity sixfold. Record revenue reported by partner Vericel, with plans for a permanent CPT code by 2027. NexoBrid approved in Australia, expanding its market presence to 45 countries.
• Funding: Strengthened balance sheet with $30 million in equity financing, providing resources to support growth strategies.

3. Forward Guidance and Outlook

• MediWound is positioned for growth in 2026, with ongoing clinical advancements and operational readiness. The company expects to reach full operational capacity for NexoBrid manufacturing by year-end 2025, which will support commercial plans for expanded market reach.

4. Challenges and Points of Concern

• Regulatory Delays: Adjustments needed for several EU trial sites may impact the overall timeline for the VALUE study.
• Government Shutdown: The recent U.S. government shutdown paused activities related to BARDA, creating uncertainty around revenue timing for Q4.
• Increased Expenses: Rising R&D and SG&A expenses may continue to pressure operating losses in the near term.

5. Notable Q&A Insights

• EscharEx Sales Projections: The updated peak sales estimate of $831 million reflects a conservative pricing model based on payer feedback, focusing on health economic outcomes rather than patient volume assumptions.
• Trial Design for DFU: The DFU study will not utilize the same centers as the VLU study, and final design updates are expected following EMA feedback.
• CPT Code Impact: The absence of a permanent CPT code may hinder adoption, but the expected approval in 2026 could enhance physician and institutional acceptance of NexoBrid.
• Competitive Landscape: While EscharEx is expected to capture market share from existing debridement methods, challenges remain due to established practices like sharp debridement and autolytic methods.

Overall, MediWound demonstrated solid progress in Q3 2025, with promising developments in both EscharEx and NexoBrid, despite facing regulatory and operational challenges.